Discrepancy in accelerated approvals for cancer drugs in the United States and Europe

This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, the discrepancy in accelerated approvals for cancer drugs in the United States and Europe comes down to the two countries having different lists of which approvals have been withdrawn, resulting in patient confusion. In addition, treatment with anticancer therapies increases the risk of developing a thromboembolic event in patients with cancer and COVID-19, and a new test for detecting cervical adenocarcinoma can find cancer that current Papanicolaou tests are less likely to pick up.